David Kutas - Bio View CEO
| BIOV Stock | ILS 26.20 0.90 3.56% |
CEO
Mr. David Kutas serves as President of Bio View Inc, a subsidiary of Bio View Ltd since June 18, 2007. He has more than 25 years of experience in multinational Medical Device companies. He served in senior management positions in Research and Development, Marketing and Sales and also served as President of Mennen Medical Inc. in the United States. Prior to joining the Company, he was the Director of Sales and Marketing of the Life Care Systems Division at Analogic Corporation since 2007.
| Age | 67 |
| Tenure | 17 years |
| Phone | 972 73 227 1025 |
| Web | https://www.bioview.com |
Bio View Management Efficiency
Bio View's management efficiency ratios could be used to measure how well Bio View manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Menachem Cohen | Storage Drop Storage | 52 | |
| Adi Eyal | One Software Technologies | 64 | |
Management Performance
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 |
Bio View Leadership Team
Elected by the shareholders, the Bio View's board of directors comprises two types of representatives: Bio View inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio View's management team and ensure that shareholders' interests are well served. Bio View's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio View's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Schwebel, CEO and Pres | ||
| Elad Kfir, Vice President of Marketing | ||
| Yulia CPA, Chief Officer | ||
| Inbal Hillel, Vice President - Operations | ||
| Yuval MSc, Ex VP | ||
| David Kutas, CEO of BioView Inc - USA and President of BioView Inc - USA |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio View a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Shares Owned By Insiders | 51.58 % | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio View financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio View security.